Knight Therapeutics Expands MINJUVI Indication to Follicular Lymphoma in Argentina and Mexico
Event summary
- Knight Therapeutics' affiliates in Argentina and Mexico submitted supplemental applications for MINJUVI (tafasitamab) to treat relapsed/refractory follicular lymphoma (FL).
- The submission seeks approval for MINJUVI in combination with lenalidomide and rituximab for FL patients after at least one prior therapy.
- MINJUVI is already approved for diffuse large B-cell lymphoma (DLBCL) in Brazil, Mexico, and Argentina, and for FL in Brazil.
- The submission follows a Phase 3 study (inMIND) showing MINJUVI + R2 reduced progression risk by 57% in relapsed/refractory FL.
The big picture
Knight Therapeutics is strategically expanding MINJUVI's reach beyond DLBCL into follicular lymphoma, a broader indication with significant unmet needs. The submission leverages prior approvals and clinical data, positioning MINJUVI as a versatile therapy in Latin America. Success here could enhance Knight's market position and revenue potential in key regions.
What we're watching
- Regulatory Approval Timing
- The pace at which ANMAT and COFEPRIS review and approve the supplemental applications will determine MINJUVI's market expansion timeline.
- Commercial Execution
- Whether Knight can effectively launch MINJUVI for FL in Argentina and Mexico, following its success in Brazil.
- Pipeline Diversification
- How MINJUVI's approval across multiple indications strengthens Knight's portfolio in Latin America.